[go: up one dir, main page]

MA31775B1 - Composé inhibiteur de la glycogène phosphorylase et composition pharmaceutique contenant ledit composé - Google Patents

Composé inhibiteur de la glycogène phosphorylase et composition pharmaceutique contenant ledit composé

Info

Publication number
MA31775B1
MA31775B1 MA32770A MA32770A MA31775B1 MA 31775 B1 MA31775 B1 MA 31775B1 MA 32770 A MA32770 A MA 32770A MA 32770 A MA32770 A MA 32770A MA 31775 B1 MA31775 B1 MA 31775B1
Authority
MA
Morocco
Prior art keywords
compound
pharmaceutical composition
glycogen phosphorylase
phosphorylase inhibiting
inhibiting compound
Prior art date
Application number
MA32770A
Other languages
Arabic (ar)
English (en)
Inventor
Pierette Banker
Scott Howard Dickerson
Dulce Maria Garrido
Steven Meagher Sparks
Francis X Tavares
Stephen Andrew Thomson
Original Assignee
Glaxosmithkline Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Llc filed Critical Glaxosmithkline Llc
Publication of MA31775B1 publication Critical patent/MA31775B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/63—One oxygen atom
    • C07D213/64—One oxygen atom attached in position 2 or 6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Saccharide Compounds (AREA)

Abstract

L'invention concerne un nouveau composé qui est un inhibiteur de la glycogène phosphorylase et son utilisation pour traiter le diabète et d'autres états associés à ce dernier. L'invention concerne également une composition pharmaceutique contenant ledit composé et des procédés pour préparer le composé et la composition pharmaceutique.
MA32770A 2007-09-28 2010-04-14 Composé inhibiteur de la glycogène phosphorylase et composition pharmaceutique contenant ledit composé MA31775B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US97586507P 2007-09-28 2007-09-28
PCT/US2008/077626 WO2009045831A1 (fr) 2007-09-28 2008-09-25 Composé inhibiteur de la glycogène phosphorylase et composition pharmaceutique contenant ledit composé

Publications (1)

Publication Number Publication Date
MA31775B1 true MA31775B1 (fr) 2010-10-01

Family

ID=40120238

Family Applications (1)

Application Number Title Priority Date Filing Date
MA32770A MA31775B1 (fr) 2007-09-28 2010-04-14 Composé inhibiteur de la glycogène phosphorylase et composition pharmaceutique contenant ledit composé

Country Status (16)

Country Link
US (1) US20100234433A1 (fr)
EP (1) EP2197845A1 (fr)
JP (1) JP2010540553A (fr)
KR (1) KR20100075568A (fr)
CN (1) CN101861303A (fr)
AU (1) AU2008309004A1 (fr)
BR (1) BRPI0817445A2 (fr)
CA (1) CA2701020A1 (fr)
CO (1) CO6321157A2 (fr)
CR (1) CR11397A (fr)
DO (1) DOP2010000088A (fr)
EA (1) EA201000392A1 (fr)
MA (1) MA31775B1 (fr)
MX (1) MX2010003442A (fr)
WO (1) WO2009045831A1 (fr)
ZA (1) ZA201002182B (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011107494A1 (fr) 2010-03-03 2011-09-09 Sanofi Nouveaux dérivés aromatiques de glycoside, médicaments contenants ces composés, et leur utilisation
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
WO2013037390A1 (fr) 2011-09-12 2013-03-21 Sanofi Dérivés amides d'acide 6-(4-hydroxyphényl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylique en tant qu'inhibiteurs de kinase
WO2013045413A1 (fr) 2011-09-27 2013-04-04 Sanofi Dérivés d'amide d'acide 6-(4-hydroxyphényl)-3-alkyl-1h-pyrazolo[3,4-b] pyridine-4-carboxylique utilisés comme inhibiteurs de kinase

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ157998A3 (cs) * 1995-11-24 1998-12-16 Smithkline Beecham S. P. A. Chinolinové deriváty, způsob jejich přípravy, farmaceutický prostředek a použití
BRPI0517567A (pt) * 2004-11-09 2008-06-17 Smithkline Beecham Corp composto ou um sal, solvato, ou derivado fisiologicamente funcional farmaceuticamente aceitável do mesmo, composição farmacêutica, usos de um composto ou um sal, solvato, ou derivado fisiologicamente funcional farmaceuticamente aceitável do mesmo e de uma composição farmacêutica, e, processo para preparar um composto

Also Published As

Publication number Publication date
EP2197845A1 (fr) 2010-06-23
ZA201002182B (en) 2011-05-25
BRPI0817445A2 (pt) 2015-10-27
EA201000392A1 (ru) 2010-10-29
AU2008309004A1 (en) 2009-04-09
JP2010540553A (ja) 2010-12-24
US20100234433A1 (en) 2010-09-16
CR11397A (es) 2010-05-24
DOP2010000088A (es) 2010-07-15
KR20100075568A (ko) 2010-07-02
CO6321157A2 (es) 2011-09-20
WO2009045831A1 (fr) 2009-04-09
MX2010003442A (es) 2010-04-21
CN101861303A (zh) 2010-10-13
CA2701020A1 (fr) 2009-04-09

Similar Documents

Publication Publication Date Title
MA31776B1 (fr) Composé inhibiteur de la glycogène phosphorylase et composition pharmaceutique contenant ledit composé
MA31775B1 (fr) Composé inhibiteur de la glycogène phosphorylase et composition pharmaceutique contenant ledit composé
WO2001081310A8 (fr) 1-aroyle-piperidinyle benzamidines
EA200900828A1 (ru) Соединения и композиции в качестве ингибиторов активности каннабиноидного рецептора 1
TN2009000059A1 (fr) Formes de dosage pharmaceutiques orales anti-manipulation contenant un analgesique opioide
MA31497B1 (fr) Nouveaux inhibiteurs peptidiques de la replication du virus de l'hepatite c
MA31963B1 (fr) Composes antagonistes du recepteur du glucagon, compositions contenant de tels composes et procedes d'utilisation
CL2011001082A1 (es) Compuestos derivados de amino-tetrahidropiranos sustituidos con heterociclos, composicion farmaceutica; y uso en el tratamiento de una afeccion seleccionada de resistencia a la insulina, hiperglicemia y diabetes de tipo 2.
MX2009000285A (es) Piperidinas sustituidas que incrementan la actividad de p53 y usos de las mismas.
MA33836B1 (fr) Compositions pharmaceutiques contenant des ligands des récepteurs sigma
MA35404B1 (fr) Composés pour le traitement de la toxicomanie
BRPI0410630A (pt) antagonista de nk1
MA31761B1 (fr) Nouveaux inhibiteurs de seh et leur utilisation
EA200870472A1 (ru) Ингибиторы 11-бета-гидроксистероид-дегидрогеназы типа 1
EA200970337A1 (ru) Ингибиторы котранспортера натрий-глюкозы 2 и способы их применения
EA199900239A1 (ru) Замещенные n-[аминоиминометил или аминометил) фенил] пропиламиды
EA200800415A1 (ru) Удаление пероксида из носителя для доставки лекарственного средства
MX2008010931A (es) Quinolonas utiles como inhibidores de sintasa de oxido nitrico inducibles.
MA32471B1 (fr) Composés de borates esters et compositions pharmaceutiques contenant des composés
DE602007007211D1 (de) Inhibitoren von11-beta-hydroxysteroiddehydrogenase 1
TNSN08038A1 (en) Cyclohexylamin isoquinolone derivatives as rho-kinase inhibitors
PE20000543A1 (es) Composiciones estabilizadas de quinapril y procedimiento para prepararlas
MX2012000566A (es) Combinaciones sinergicas de principios activos con feniltriazoles.
BRPI0806789B8 (pt) composto ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, e, uso de um composto ou de um sal farmaceuticamente aceitável do mesmo
BRPI0714885B8 (pt) compostos terapêuticos e seu uso